Data

Rate of Sovaldi non-adherence points to need for patient support

Rate of Sovaldi non-adherence points to need for patient support

By

A mélange of new treatments awaiting approval and a lack of patient support are driving down drug utilization for Gilead's HCV blockbuster, according to a new study.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.

Nurses undeterred by internet bans at work: study

Nurses undeterred by internet bans at work: study

By

Healthcare workers seek out health-related information on their own time, and through internet connections other than ones offered by their employers.

Drug spend will continue to rise through 2023

Drug spend will continue to rise through 2023

By

The numbers folks at the Centers for Medicare and Medicaid Services anticipate sluggish growth in US healthcare spend, but prescriptions look ready to take off.

CDC: Every state has an obesity problem

The latest data shows an overall widening of the US.

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low on doc awareness

By

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Doctors do not care about your Fitbit

Tech site Venturebeat, citing anonymous sources, says doctors are too overwhelmed and weary to evaluate how many steps you took this weekend.

US diabetes risk jumps to 40%

US diabetes risk jumps to 40%

By

African-American women had the highest risk of being diagnosed with diabetes—55%. Hispanic men and women were close behind, carrying a 50% risk of being diagnosed with diabetes.

Healthy-habit trackers have short-lived appeal

A study indicates consumers stop using them at the six-month mark.

GAO tallies cost-effective interventions

GAO tallies cost-effective interventions

By

Half-measures, like diabetes educational materials without a part B, fared poorly.

Open Payments website 'temporarily' taken offline

The pharma payment verification site has been temporarily shut down by CMS due to incorrect information, ProPublica reported today.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

By

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to display Sunshine payment data

By

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like meals, travel, gifts, consulting and research

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

Next target for hep. C drugmakers: co-infections

Next target for hep. C drugmakers: co-infections

By

An international AIDS conference this weekend kicked off a new battle in the war against hepatitis C: demonstrating high cure rates in those who are co-infected.

CME commercial support cuts narrow

CME commercial support cuts narrow

By

The rate of decrease in industry's budget for continuing medical education (CME) slowed last year.

Industry trims support for CME

Industry reined in commercial support for CME in 2013—the sixth consecutive annual decrease—data released today by the ACCME show.

Study links Actos with delayed dementia

German healthcare data from 2004 through 2010 across a data set that included 146,000 patients shows dementia surfaced later among Actos patients.

FDA quicker on approval trigger than EU: study

The FDA began its drug review at a median time of 103 days sooner than the EMA. Being first, researchers found, often resulted in quicker approval.

Generics trigger wallet shock

Prices for some generics are rising, thanks to limited competition.

Healthcare organization makes big data bigger

Credit card and loyalty program purchases will help Carolinas HealthCare System flag potential patient behavior issues.

Zohydro's second act

Zogenix is working on a less easily abused formulation of its controversial prescription painkiller.

CDC: US is biggest Rx opioid market

CDC: US is biggest Rx opioid market

By

The Centers of Disease Control reports that prescribers wrote enough painkiller prescriptions to give one bottle to every adult in the US in 2012.

Facebook's clinical trial

The networking site's emotion experiment rankles some in the science and political communities.

IMS to buy Cegedim CRM

IMS to buy Cegedim CRM

By

IMS is offering $520 million cash to add Cegedim's CRM and strategic data business. Cegedim says it will use the money to pay down debt.

Drug sales to hit $1T by 2020, researchers say

Drug sales to hit $1T by 2020, researchers say

By

EvaluatePharma's World Preview 2014 has pharma soaring to new lucrative heights in six years' time, buoyed by biologics and a formidable pipeline.

Vertex to submit CF drug combo to FDA this year

Vertex to submit CF drug combo to FDA this year

By

Phase III results showing improved lung function among cystic fibrosis patients using a combination of Kalydeco and lumacaftor means drugmaker Vertex is filing the two-part drug for FDA approval during the fourth quarter.

Sifting social media for the  "why" behind Rx switching

Sifting social media for the "why" behind Rx switching

By

Platform lets pharma firms mine big data, and monitor whether millions spent on ad campaigns or medical education are having the desired effect

Triglycerides, not HDL, may be cardio bad guys

Gene mutations lead researchers to rethink ways to protect the heart.

Study finds Alzheimer's misunderstood

Study finds Alzheimer's misunderstood

By

An Alzheimer's Association survey finds 59% think the degenerative disease is just part of aging.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters